Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Social Psychiatry and Psychiatric Epidemiology
Published in: Social Psychiatry and Psychiatric Epidemiology 7/2009

01-07-2009 | ORIGINAL PAPER

Putting the ‘Q’ in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures

Authors: Rachel Mann, MSc, Prof. Simon Gilbody, DPhil, MRCPsych, Prof. David Richards, PhD

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 7/2009

Login to get access

Abstract

Background

Generic health preference measures that capture quality of life improvements in depression are important for economic analysis of new technologies.

Aim

To compare two widely used preference measures, the EQ-5D and SF-6D, in terms of their dimensions and health utility values.

Method

EQ-5D and SF-6D data collected from 114 patients with depression, who participated in a cluster, randomised controlled trial to evaluate a collaborative care intervention in UK, primary care practices. Utilities were examined across the whole sample and by level of depression severity using the PHQ-9.

Results

Depression was associated with disutility at baseline. At 3 month follow-up mean utility increased 0.147 for EQ-5D and 0.082 for SF-6D. Health gains were observed in patients in remission from depression and those with the mildest level of depression severity.

Conclusions

Both generic preference measures were sensitive to health gains in depression within a relatively short follow-up period; larger health gain was observed for the EQ-5D.
Appendix
Available only for authorised users
Literature
1.
Brazier J, Deverill M, Green C, Harper R, Booth A (1999) A review of the use of health status measures in economic evaluation. Health Technol Assess 3:1–164
2.
Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292PubMedCrossRef
3.
Brazier JE, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, Sculpher M, Tsuchyia A (2005) Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 4(4):201–208PubMedCrossRef
4.
Brazier JE, Ratcliffe J, Tsuchiya A, Salomon J (2007) Measuring and valuing health benefits for economic evaluation. Oxford University Press, Oxford
5.
Brazier JE, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13:873–884PubMedCrossRef
6.
CCOHTA (1997) Guidelines for the economic evaluation of pharmaceuticals. Canadian Coordinating Office for Health Technology Assessment, Ottawa
7.
Donaldson C, Currie G, Mitton C (2002) Cost effectiveness analysis in health care: contraindications. BMJ 325:891–894PubMedCrossRef
8.
First M, Spitzer R, Gibbon M, Williams J (1996) Structured clinical interview schedule for DSM-IV axis/disorders, Clinical Version, (SCID-CV). American Psychiatric Press, Washington DC
9.
Gilbody S, Richards D, Barkham M (2007) Diagnosing depression in primary care using self-completed instruments: UK validation of PHQ-9 and CORE-OM. Br J Gen Pract 57:650–652PubMed
10.
Gilbody S, Richards D, Brearly S, Hewitt C (2007) Screening for depression in medical settings with the patient health questionnaire (PHQ): a diagnostic meta-analysis. J Gener Int Med (in press)
11.
Gold MR (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
12.
Gunther OH, Roick C, Angermeyer MC, Konig H-H (2008) The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord (in press)
13.
Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, Parry G, Rooney G, Sutcliffe P (2006) Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess 10:iii, xi-xiv, 1–168PubMed
14.
Kroenke K, Spitzer R (2002) The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Ann 32:509–521
15.
Lamers LM, Bouwmans C, van Straten A, Donker M, Hakkaart L (2006) Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ 15:1229–1236PubMedCrossRef
16.
17.
Longworth L, Bryan S (2003) An emprical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 12:1061–1067PubMedCrossRef
18.
NICE (2007) Antenatal and postnatal mental health: clinical guideline (CG45). HMSO, London
19.
NICE (2004) Depression: core interventions in the management of depression in primary care and secondary care. HMSO, London
20.
NICE (2004) Guide to the methods of technology appraisal. HMSO, London
21.
Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M (2004) Quality of life assessments in major depressive disorder: a review of the literature. General Hospital Psychiatry 26:13–17PubMedCrossRef
22.
Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, Chatwin J, Goddard J, Thornett A, Smith H, Campbell M, Thompson C (2005) A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess 9:1–134PubMed
23.
Rawlins MD (2004) NICE work—providing guidance to the British National Health Service. N Engl J Med 351:1383–1385PubMedCrossRef
24.
Rawlins MD, Culyer AJ (2004) National Institute for clinical excellence and its value judgments. BMJ 329:224–227PubMedCrossRef
25.
Revicki DA, Wood M (1998) Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 48:25–36PubMedCrossRef
26.
Richards D, Lovell K, Gilbody S, Gask L, Torgerson D, Barkham M, Bland M, Bower P, Lankshear A, Simpson A, Fletcher J, Escott D, Henessey S, Richardson R (2007) Collaborative care for depression in UK primary care: a randomized controlled trial. Psychol Med (in press)
27.
Sapin C, Fantino B, Nowicki M-L, Kind P (2004) Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2:20PubMedCrossRef
28.
Donald Sherbourne C, Unutzer J, Schoenbaum M, Duan N, Lenert LA, Sturm R, Wells KB (2001) Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Med Care 39:1246–1259PubMedCrossRef
29.
Sobocki P, Ekman M, Agren H, Krakau I, Runeson B, Martensson B, Jonsson B (2007) Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 10:153–160PubMedCrossRef
30.
SPSS (2005) SPSS Base 14.0 User’s Guide. SPSS Inc, Chicago
31.
The EuroQol Group (1990) EuroQol-a new facility for the measurement of health related quality of life. The EuroQol Group. Health Policy 16:199–208CrossRef
32.
Thomas CM, Morris S (2003) Cost of depression among adults in England in 2000. Br J Psychiatry 183:514–519PubMedCrossRef
33.
Ware JE, Gandek B, Kosinski M, Snow KK (1993) SF-36 health survey: manual and interpretation guide. The Health Institute New England Medical Center, Boston
34.
Williams A (1995) The measurement and valuation of health: a chronicle. discussion paper 136. In: Centre for health economics. York Health Economics Consortium, The University of York
35.
World Health Organisation (2001) The World Health Report 2001: mental health: new understanding: new hope. World Health Organisation, Geneva
Metadata
Title
Putting the ‘Q’ in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures
Authors
Rachel Mann, MSc
Prof. Simon Gilbody, DPhil, MRCPsych
Prof. David Richards, PhD
Publication date
01-07-2009
Publisher
Steinkopff-Verlag
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 7/2009
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-008-0463-5

Other articles of this Issue 7/2009

Social Psychiatry and Psychiatric Epidemiology 7/2009 Go to the issue

ORIGINAL PAPER

Vocational rehabilitation for subjects with severe mental illnesses in Germany

ORIGINAL PAPER

Disengagement from mental health services

ORIGINAL PAPER

Bed utilization in two differently organized community mental health services in Northern Norway: the VELO-project

ORIGINAL PAPER

Frequency of subsyndromal symptoms and employment status in patients with bipolar disorder

ORIGINAL PAPER

GHQ increases among Scottish 15 year olds 1987–2006

ORIGINAL PAPER

Satisfaction and burnout among staff of crisis resolution, assertive outreach and community mental health teams